Sorafenib Gemcitabine
Sorafenib Gemcitabine - Related Videos
09:18
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
0 Views •
2026
This protocol uses a multichamber bed for parallel magnetic resonance imaging (MRI) of up to four animals to detect pancreatic adenocarcinoma tumors in genetically engineered mouse models. This multianimal MRI protocol is fast and cost-effective for detecting and measuring tumors, facilitating animal selection for preclinical studies and longitudinal monitoring of tumor growth.
03:21
Zebrafish Patient-Derived Xenograft (zPDX): A Cancer Model
0 Views •
2023
This video describes the technique to create a zebrafish patient derived xenograft model. In the sample protocol, we assess the efficiency of the drugs Gemcitabine and Navitoclax on the pancreatic tumor xenograft model.
12:41
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
0 Views •
Cited by 14 •
2022
This protocol describes a semi-automated method for medium- to high-throughput organoid drug screenings and microscope-agnostic, automated image analysis software to quantify and visualize multiparametric, single-organoid drug responses to capture intratumor heterogeneity.
09:58
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
0 Views •
Cited by 25 •
2016
Here we describe a protocol aimed at investigating the impact of aberrant splicing on drug resistance in solid tumors and hematological malignancies. To this goal, we analyzed the transcriptomic profiles of parental and resistant in vitro models through RNA-seq and established a qRT-PCR based method to validate candidate genes.
FAQs
Potential benefit from the combination comes from attacking tumor biology at two levels. Sorafenib can reduce RAF- and receptor tyrosine kinase-driven signaling associated with proliferation and angiogenesis, while gemcitabine directly creates replication stress through its intracellular metabolites. Studying both effects together helps researchers ask whether signaling suppression changes the tumor-cell response to DNA-directed chemotherapy.
Gemcitabine’s effects depend on what happens after it enters a cell. Phosphorylation produces the active intracellular forms described in the treatment model, enabling ribonucleotide reductase inhibition and DNA incorporation. These linked steps connect drug processing with impaired DNA replication, so experiments can evaluate cytotoxicity in relation to the cellular mechanism rather than treating gemcitabine exposure as an isolated event.
Researchers can compare responses to the individual agents with responses to their combination. This comparison helps determine whether the paired treatment produces a distinct cytotoxicity pattern, changes tumor response in models, or reveals resistance that is not apparent with either agent alone. The same framework supports investigation of how targeted signaling inhibition relates to chemotherapy response.
Evaluation can proceed across complementary research settings: cell models can test cytotoxicity and treatment interactions, animal models can assess tumor response, and clinical studies can examine treatment response. Moving across these settings allows investigators to connect cellular effects with responses in tumors and with evidence generated in clinical research, while keeping each model’s outcome distinct.
Results should be interpreted through several endpoints rather than a single measure. Cytotoxicity indicates effects on cancer cells, tumor response captures behavior in an animal or clinical context, treatment-interaction analyses address the consequence of combining agents, and resistance studies examine why effects may diminish. Together, these outcomes provide a broader picture of therapeutic performance.
It serves as a model for examining how targeted therapies can be integrated with chemotherapy. Sorafenib-related pathway suppression and gemcitabine-related disruption of DNA replication give researchers complementary processes to track in the same study. This makes the combination useful for connecting molecular signaling, drug effects, tumor response, and resistance within cancer-treatment research.